Exploring regulatory data sets of the Comirnaty vaccine - 9e

Summing what we have learned about the pharmacokinetics of Cominarty

We close our leisurely stroll through the properties of the two lipid nanoparticles (LNP) and modified messenger mRNA of Comirnaty.

Well, what do you know? It feels like yesterday, and we have already written loads about Comirnaty. So, have our readers, who have commented in their droves, Just look at this diagram drawn by Picasso Heneghan:

This is a list of firm points and 15 questions we have established so far:

The lipid “excipients” ALC-0315 and ALC-0159 were new. Regulators note the limited experience with these compounds.

1. Whose job is it to close the gap in evidence and ensure patient safety when new experimental compounds are included in vaccines?

Experience of their use in humans was limited. They act as the carriers; the RNA is a different story. The metabolites were found everywhere in the rats’ organs (liver, spleen, ovaries and so on).

The significance of their widespread distribution is unclear for humans, but the concentrations were very high in the liver and ovaries and almos…